Jacobio Pharma: More Thinking on Valuation
Our DCF analysis of Jacobio Pharma results in a US$1.1B pre-money valuation based on the company's lead compounds and the AbbVie license agreement....
359 Views
Jacobio Pharma: Focus on Novel Targets
An in-depth overview of the proposed listing of Jacobio Pharmaceuticals using a framework that touches on the science, market opportunity,...
338 Views
Tesla: S&P500 Inclusion Secured?
On 22 July, Tesla Motors (TSLA US) reported a profit for Q2 2020 making it the fourth consecutive quarterly profit. Hitting that milestone makes...
561 Views
S&P 500: Long-Term Oversold
Major indexes broke below the key support levels we were watching on the Nasdaq Composite (8,264), S&P 500 (2,855), DJI (24,681) and Russell...
331 Views
InnoCare Pharma IPO Initiation: Promising Prognosis
InnoCare Pharma Ltd (1576300D CH) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...
383 Views